IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line ...
IO Biotech announced promising Phase 2 data for IO102-IO103 in combination with KEYTRUDA® in SCCHN patients at ESMO 2024, showing a 44.4% ORR and 6.6-month median PFS, with no new safety concerns.
Related Clinical Trials
Reference News
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line ...
IO Biotech announced promising Phase 2 data for IO102-IO103 in combination with KEYTRUDA® in SCCHN patients at ESMO 2024, showing a 44.4% ORR and 6.6-month median PFS, with no new safety concerns.